<DOC>
	<DOCNO>NCT02665689</DOCNO>
	<brief_summary>The aim prospective randomize study investigate whether intensified diabetic control program lead well final visual acuity less frequent diabetic ocular complication patient diabetic retinopathy compare normal diabetic treatment .</brief_summary>
	<brief_title>Influence Diabetes Control Treatment Diabetic Macular Edema With Ranibizumab</brief_title>
	<detailed_description>Patints diabetic macular edema ( DME ) treat intravitreal ranibizumab injection effect optimal control internal factor ( eg . glycemia , blood presure etc ) final functional ( best correct visual acuity-CBVA ) morphological ( central retinal thickness-CRT ) investigate . Patients randomize two group : Group intensify diabetic control follow investigate monthly department diabetology , endocrinology nutritional medicine ( Campus Benjamin Franklin ) Berlin aim reach optimal glycemic control define HbA1c &lt; 6,5 % . Further , triglycerides value &lt; 140 mg/dl blood presure &lt; 140/90 mmHg pursue . Second group patient follow general practitioner study center blood sample take quarterly without active medical intervention . BCVA , CRT number require ranibizumab injection evaluate compare study group .</detailed_description>
	<mesh_term>Macular Edema</mesh_term>
	<mesh_term>Edema</mesh_term>
	<mesh_term>Ranibizumab</mesh_term>
	<criteria>Patients diabetic macular edema relevant visual acuity OCT central retinal thickness ≥ 250µm HbA1c &gt; 6,5 % initial visit BCVA &gt; 0.8 &gt; 0.05 Age ≥18 year Written patient inform consent give Previous treatment intravitreal drug last 6 month Vitreous hemorrhage consequence proliferative retinopathy Pregnancy Blood pressure ≥ 180/100 ( uncontrolled pressure pharmacological therapy ) Chronic systemic ocular inflammatory/autoimmune disease ( e.g . inflammatory bowel disease , Addison´s disease , Cushing Syndrome , Uveitis ) Systemic cortisone antiVEGF therapy Acute systemic ocular infectious disease</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2016</verification_date>
	<keyword>Diabetic Macular Edema , Ranibizumab , Visual Acuity , Diabetic Control ,</keyword>
</DOC>